Dermapharm Holding SE (DMP.DE)

EUR 37.2

(1.64%)

Operating Income Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual operating income in 2023 was 182.89 Million EUR , down -17.79% from previous year.
Dermapharm Holding SE's latest quarterly operating income in 2024 Q2 was 40.24 Million EUR , down -41.41% from previous quarter.
Dermapharm Holding SE reported an annual operating income of 243.68 Million EUR in 2022, down -18.35% from previous year.
Dermapharm Holding SE reported an annual operating income of 298.46 Million EUR in 2021, up 118.09% from previous year.
Dermapharm Holding SE reported a quarterly operating income of 68.69 Million EUR for 2024 Q1, up 118.67% from previous quarter.
Dermapharm Holding SE reported a quarterly operating income of 51.18 Million EUR for 2023 Q3, up 392.0% from previous quarter.

Annual Operating Income Chart of Dermapharm Holding SE (2023 - 2014)

Historical Annual Operating Income of Dermapharm Holding SE (2023 - 2014)

Year	Operating Income	Operating Income Growth
2023	182.89 Million EUR	-17.79%
2022	243.68 Million EUR	-18.35%
2021	298.46 Million EUR	118.09%
2020	136.85 Million EUR	14.51%
2019	119.51 Million EUR	11.17%
2018	107.5 Million EUR	16.71%
2017	92.11 Million EUR	6.13%
2016	86.79 Million EUR	42.84%
2015	60.76 Million EUR	40.48%
2014	43.25 Million EUR	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	40.24 Million EUR	-41.41%
2024 Q1	68.69 Million EUR	118.67%
2023 Q3	51.18 Million EUR	392.0%
2023 Q4	31.41 Million EUR	-38.63%
2023 FY	200.34 Million EUR	-17.79%
2023 Q1	84.29 Million EUR	9.74%
2023 Q2	10.4 Million EUR	-87.66%
2022 Q1	58.08 Million EUR	-42.7%
2022 FY	243.68 Million EUR	-18.35%
2022 Q2	32.94 Million EUR	-43.29%
2022 Q4	76.81 Million EUR	1.28%
2022 Q3	75.84 Million EUR	130.23%
2021 Q4	101.37 Million EUR	19.19%
2021 FY	298.46 Million EUR	118.09%
2021 Q2	60.25 Million EUR	16.38%
2021 Q3	85.05 Million EUR	41.16%
2021 Q1	51.77 Million EUR	38.17%
2020 Q4	37.47 Million EUR	8.46%
2020 FY	136.85 Million EUR	14.51%
2020 Q3	34.55 Million EUR	37.62%
2020 Q2	25.1 Million EUR	-36.8%
2020 Q1	39.72 Million EUR	22.25%
2019 Q2	28.49 Million EUR	-0.95%
2019 FY	119.51 Million EUR	11.17%
2019 Q1	28.76 Million EUR	13.83%
2019 Q4	32.49 Million EUR	9.18%
2019 Q3	29.76 Million EUR	4.46%
2018 Q4	25.26 Million EUR	-10.63%
2018 FY	107.5 Million EUR	16.71%
2018 Q2	23.54 Million EUR	-22.59%
2018 Q1	30.41 Million EUR	40.35%
2018 Q3	28.27 Million EUR	20.08%
2017 Q2	21.77 Million EUR	-13.44%
2017 Q3	23.5 Million EUR	7.96%
2017 Q1	25.15 Million EUR	15.72%
2017 FY	92.11 Million EUR	6.13%
2017 Q4	21.67 Million EUR	-7.81%
2016 FY	86.79 Million EUR	42.84%
2016 Q4	21.73 Million EUR	0.0%
2015 FY	60.76 Million EUR	40.48%
2014 FY	43.25 Million EUR	0.0%

Peer Operating Income Comparison of Dermapharm Holding SE

Name	Operating Income	Operating Income Difference
MPH Health Care AG	15.7 Million EUR	-1064.93%
Apontis Pharma AG	-15.1 Million EUR	1311.219%
Evotec SE	-47.5 Million EUR	484.983%
MERCK Kommanditgesellschaft auf Aktien	3.6 Billion EUR	94.932%
PharmaSGP Holding SE	40.91 Million EUR	-347.021%
SynBiotic SE	-7.58 Million EUR	2512.228%